May-Thurner syndrome (MTS), also known as Cockett's syndrome, is an anatomical variant in which the left common iliac vein is compressed between the right common iliac artery and the fifth lumbar vertebral body, leading to venous outflow obstruction, intimal hyperplasia, and predisposition to left-sided iliofemoral deep vein thrombosis (DVT). [1-3] It accounts for 2–5% of all DVTs and is likely underdiagnosed. [1][4]
The following figure demonstrates the diagnosis and endovascular treatment of MTS, including CT imaging of the iliac vein compression, venography, catheter-directed thrombectomy, stenting, and IVUS assessment:
1. History
- Left lower extremity swelling — the cardinal symptom; present in ~70% of patients, often painless initially [6]
- Onset: acute (days) with DVT, or chronic/progressive with venous stasis
- Timing: peripartum, postoperative, or after initiation of oral contraceptives (mean onset ~5 weeks after starting OCPs) [7]
- Pain: dull aching, heaviness, or venous claudication in the left leg
- Associated symptoms: skin discoloration, venous stasis ulcers, paresthesias [2]
- Important negatives: absence of trauma, cellulitis, bilateral symptoms, systemic edema causes (CHF, nephrotic syndrome, cirrhosis)
2. Alarm Features
- Acute dyspnea, tachycardia, pleuritic chest pain → concern for pulmonary embolism (PE), a life-threatening complication [8-9]
- Phlegmasia cerulea dolens (massive swelling, cyanosis, impending venous gangrene)
- Rapid progression of swelling despite therapeutic anticoagulation — suggests underlying anatomical obstruction [10]
- New oxygen requirement with asymmetric leg swelling [9]
3. Medications
- Contributors to DVT in MTS:
- Oral contraceptives and estrogen-containing therapies are major precipitants, especially in young women with undiagnosed MTS anatomy [7]
- Hormone replacement therapy, tamoxifen
- Treatment medications:
- Anticoagulation: LMWH (initial), transitioning to warfarin or DOACs; duration typically ≥6–12 months, with lifelong anticoagulation recommended after multiple DVTs [11]
- Post-stent antithrombotic therapy: anticoagulation preferred for 6–12 months; antiplatelet therapy associated with improved stent patency [11]
- Cautions: Anticoagulation alone is often insufficient in MTS — the underlying mechanical obstruction persists and predisposes to recurrent DVT (aHR 2.26) [7][12]
4. Diet
- No specific dietary triggers for MTS
- Adequate hydration to reduce venous stasis
- Weight management — obesity (mean BMI ~27 in MTS patients) contributes to venous stasis and DVT risk [6]
- Avoid prolonged immobility during long-haul travel; encourage ambulation
5. Review of Systems
- Cardiovascular: dyspnea, chest pain, palpitations (PE screening)
- Extremities: unilateral leg swelling, pain, heaviness, skin changes, ulceration
- GU/Pelvic: pelvic pain or congestion symptoms (pelvic venous disorder can coexist)
- Hematologic: history of prior VTE, easy bruising, family history of clotting disorders
- OB/GYN: pregnancy status, OCP use, peripartum timing
6. Collateral History and Family History
- Family history of VTE or inherited thrombophilia (Factor V Leiden, prothrombin gene mutation, protein C/S deficiency, antithrombin deficiency) [1]
- History of recurrent miscarriages (antiphospholipid syndrome)
- Social context: prolonged immobility, recent travel, sedentary occupation
- Medication reconciliation: confirm estrogen-containing medications
7. Risk Factors
- Female sex — 78% of MTS patients in the RIETE registry were female [12]
- Young age — mean age 42 years in MTS vs 62 years in non-MTS DVT [12]
- Estrogen exposure — OCPs, pregnancy, peripartum period [7][12]
- Obesity (BMI >25) [6]
- Recent surgery or immobilization [1]
- Inherited thrombophilia — coexisting hypercoagulable states compound risk [7][13]
- Anatomical variant — asymptomatic iliac vein compression is common (~22% of cadaveric studies), but clinical MTS develops in a subset [4]
8. Differential Diagnosis
- DVT from other causes (provoked or unprovoked without compression) — most common mimic; distinguished by advanced imaging showing iliac vein compression
- Cellulitis — erythema, warmth, fever; no venous obstruction on imaging
- Lymphedema — non-pitting, chronic, often bilateral or post-surgical
- Baker's cyst rupture — posterior knee pain, popliteal fullness on ultrasound
- Chronic venous insufficiency — bilateral, varicosities, without acute DVT
- Extrinsic iliac vein compression from pelvic mass (tumor, lymphadenopathy, retroperitoneal fibrosis) — CT/MRI distinguishes
- IVC anomalies — agenesis or duplication causing venous stasis [13]
- Pelvic venous congestion syndrome — chronic pelvic pain, ovarian vein reflux
9. Past Medical History
- Prior DVT or PE (especially left-sided, recurrent, or "unprovoked")
- History of post-thrombotic syndrome
- Prior pelvic or abdominal surgery
- Thrombophilia diagnosis
- Pregnancy history
- Chronic venous insufficiency or varicose veins
10. Physical Exam
- Vital signs: tachycardia and hypoxia suggest PE
- Left lower extremity:
- Unilateral or asymmetric edema (left > right) — the hallmark finding [6][9]
- Pitting edema, calf tenderness, positive Homan's sign (low sensitivity/specificity)
- Skin changes: hyperpigmentation, induration, venous ectasia, stasis dermatitis
- Venous ulceration in chronic cases
- Measure and compare bilateral calf and thigh circumferences (>2 cm difference is significant)
- Phlegmasia: tense swelling, cyanotic discoloration, diminished pulses (surgical emergency)
- Pelvic collateral veins may be visible on the abdominal wall in chronic obstruction
11. Lab Studies
- D-dimer: sensitive but nonspecific; useful to rule out DVT in low-probability patients
- CBC, BMP, coagulation studies (PT/INR, aPTT) — baseline before anticoagulation
- Thrombophilia workup (in selected patients, especially young/recurrent DVT):
- Factor V Leiden, prothrombin gene mutation
- Protein C, Protein S, antithrombin III levels
- Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein I) [1][7]
- Troponin, BNP — if PE suspected
- Hepatic/renal function — rule out systemic causes of edema
12. Imaging
- First-line: Venous duplex ultrasound (VDUS) — identifies infrainguinal DVT but has limited sensitivity for iliac vein pathology; indirect signs include loss of respiratory phasicity and attenuated flow velocities [1]
- CT venography (CTV): Sensitivity 96%, specificity 95% for iliac vein obstruction — the recommended modality for diagnosing MTS; shows the compression of the left common iliac vein by the right common iliac artery [1][6][14]
- MR venography (MRV): Alternative to CTV, especially in patients with renal insufficiency (non-contrast 3D TSE sequences available); superior anatomy above the inguinal ligament [15-16]
- Intravascular ultrasound (IVUS): The most sensitive and specific modality for detecting and quantifying iliac vein stenosis; superior to venography for stent sizing and treatment planning; recommended when invasive venography is performed [16-17]
- Conventional venography: Historical gold standard; now primarily used during endovascular intervention [16]
- CTPA: Add if PE is suspected [9]
13. Special Tests
- Villalta Score — diagnoses and grades post-thrombotic syndrome severity (0–4 = no PTS; 5–9 = mild; 10–14 = moderate; ≥15 or ulcer = severe) [18-19]
- Wells Score for DVT — pre-test probability assessment
- CEAP classification — for chronic venous disease staging
- Venous Clinical Severity Score (VCSS) — validated for assessing clinical change in chronic venous disease [20]
- Pressure gradient measurement — a gradient >2 mmHg across the iliac vein compression is significant [3]
14. ECG
- Obtain ECG if PE is suspected
- Findings suggestive of PE: sinus tachycardia, right axis deviation, S1Q3T3 pattern, right bundle branch block, T-wave inversions in anterior leads (V1–V4)
- ECG is otherwise not directly diagnostic for MTS
15. Assessment
MTS is an underdiagnosed anatomical cause of left-sided iliofemoral DVT that should be suspected in any patient — particularly young women — presenting with left lower extremity DVT, especially when "unprovoked" or occurring in the setting of estrogen exposure. [1][12] The RIETE registry confirmed MTS as an independent predictor of recurrent DVT (aHR 2.26; 95% CI 1.02–5.01) despite aggressive therapy. [12] Complications include PE, post-thrombotic syndrome, chronic venous insufficiency, and rarely phlegmasia cerulea dolens. [2][8]
Key clinical pearl: Anticoagulation alone is often inadequate because the underlying mechanical compression persists, leading to high recurrence rates. Delayed diagnosis is common — median time from DVT to MTS diagnosis was 0.65 months in one adolescent series, with patients experiencing clinical worsening during the delay. [10]
16. Treatment Plan
- Acute DVT management:
- Initiate therapeutic anticoagulation (LMWH or unfractionated heparin)
- Consider IVC filter placement if anticoagulation is contraindicated or prior to catheter-directed intervention with large thrombus burden [2][8]
- Definitive treatment — endovascular intervention:
- Catheter-directed thrombolysis (CDT) or pharmacomechanical thrombectomy to clear acute thrombus [21-22]
- Balloon angioplasty and iliac vein stenting of the underlying compression — the preferred definitive treatment [21][23-24]
- One-stop mechanical thrombectomy + simultaneous stenting showed superior outcomes: 81.5% 6-month patency vs 32% with traditional CDT alone, and lower PTS incidence (11% vs 76%) [22]
- Primary patency rates for iliac vein stents: 84–94% at 12 months in adolescent/young adult series [24]
- Post-procedural antithrombotic therapy:
- Anticoagulation for 6–12 months minimum; LMWH preferred for first 2–6 weeks post-stent [11]
- Lifelong anticoagulation recommended after multiple DVTs [11]
- Antiplatelet therapy associated with improved stent patency [11]
- Non-thrombotic MTS (symptomatic compression without DVT):
- Compression stockings, leg elevation
- Iliac vein stenting for symptomatic patients with >50% stenosis [24]
17. Disposition
- Admit for:
- Acute iliofemoral DVT requiring catheter-directed intervention
- Hemodynamic instability or concurrent PE
- Phlegmasia cerulea dolens (surgical emergency)
- Need for IVC filter placement
- Observation for:
- Discharge criteria:
- Stable on therapeutic anticoagulation
- Post-stent patients with patent stent, resolved symptoms, and adequate anticoagulation plan
- Outpatient vascular surgery/interventional radiology follow-up arranged
- Specialist consultation triggers:
- Vascular surgery or interventional radiology for all confirmed MTS cases
- Hematology for thrombophilia workup in young patients or recurrent DVT [7][10]
18. Follow Up / Return Precautions
- Follow-up timing:
- Vascular surgery/IR within 1–2 weeks post-discharge
- Duplex ultrasound surveillance of stent patency at 1, 3, 6, and 12 months, then annually [8][24]
- IVC filter retrieval at ~4 weeks if placed [8]
- Return precautions — instruct patients to seek immediate care for:
- Worsening leg swelling, pain, or skin color changes
- Shortness of breath, chest pain, hemoptysis (PE)
- Signs of bleeding (hematuria, melena, excessive bruising) while on anticoagulation
- Patient counseling:
- Discontinue estrogen-containing contraceptives; discuss alternative contraception [7]
- Importance of anticoagulation adherence
- Compression stocking use for PTS prevention
- Expected recovery: swelling typically improves within days to weeks post-stent; full resolution may take months
- MTS is a permanent anatomical risk factor — long-term anticoagulation may be needed in selected cases [12][25]
References
1. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review. — Chopard R, Albertsen IE, Piazza G. The Journal of the American Medical Association. 2020.
2. May-Thurner Syndrome: Update and Review. — Mousa AY, AbuRahma AF. Annals of Vascular Surgery. 2013.
3. May-Thurner Anatomy in Patients With Chronic Thromboembolic Pulmonary Hypertension: An Important Clinical Association. — Al-Otaibi M, Vaidy A, Vaidya A, et al. JACC. Cardiovascular Interventions. 2021.
4. May-Thurner Syndrome: History of Understanding and Need for Defining Population Prevalence. — Harbin MM, Lutsey PL. Journal of Thrombosis and Haemostasis : JTH. 2020.
5. Acute Deep Vein Thrombosis. — Ian Del Conde, James F. Benenati Endovascular Interventions. 2018.
6. Demographic Characteristics, Clinical Manifestations, and Treatment Outcomes of May-Thurner Syndrome: A Five-Year Retrospective Analysis Using Computed Tomography Venography in a Chinese Population. — Lan YQ, Chen YM, Lan KS, Feng N, Xi ZF. Current Medical Research and Opinion. 2024.
7. Symptomatic Ileofemoral DVT After Onset of Oral Contraceptive Use in Women With Previously Undiagnosed May-Thurner Syndrome. — Murphy EH, Davis CM, Journeycake JM, DeMuth RP, Arko FR. Journal of Vascular Surgery. 2009.
8. Deep Vein Thrombosis Due to May-Thurner Syndrome: A Case Report. — Meng Y, Qin H, Ma Q, et al. BMC Cardiovascular Disorders. 2020.
9. A Rare Emergency Department Diagnosis of May-Thurner Syndrome. — Paladugu S, Farrell J, Ajhar A, Weissman C. The American Journal of Emergency Medicine. 2025.
10. Diagnosis, Clinical Characteristics, and Treatment Modalities of Adolescent May-Thurner Syndrome-Associated Deep Venous Thrombosis. — Cohen CT, Kirk S, Desai SB, Kukreja KU, Srivaths L. Journal of Pediatric Hematology/Oncology. 2021.
11. Society of Interventional Radiology Position Statement on the Management of Chronic Iliofemoral Venous Obstruction With Endovascular Placement of Metallic Stents. — Vedantham S, Weinberg I, Desai KR, et al. Journal of Vascular and Interventional Radiology : JVIR. 2023.
12. Clinical Characteristics and Impact of May-Thurner Syndrome in Patients With Proximal Deep Vein Thrombosis: Insights From the RIETE Registry. — Varona JF, Ochoa Chaar CI, Pedrajas JM, et al. Angiology. 2025.
13. Lower Extremity Venous Thrombosis in Patients Younger Than 50 Years of Age. — Kreidy R, Salameh P, Waked M. Vascular Health and Risk Management. 2012.
14. Iliac Vein Obstruction: Accuracy of Direct Multidetector Computed Tomographic Venography and Duplex Ultrasound. — Abdalla Ahmed S, Elbadawy A, Khalaf LMR, Samy M. The British Journal of Radiology. 2025.
15. Using Non-Contrast-Enhanced Magnetic Resonance Venography for the Evaluation of May-Thurner Syndrome in Patients With Renal Insufficiency: A Case Report. — Hsu YC, Huang YK, Hsu LS, Chen PY, Chen CW. Medicine. 2019.
16. Revisiting the Open Vein Hypothesis to Reduce the Postthrombotic Syndrome: Implications for Multidisciplinary Care and Research: A Scientific Statement From the American Heart Association. — Li W, Vedantham S, Jaffer FA, et al. Circulation. 2025.
17. ACR Appropriateness Criteria® Lower Extremity Chronic Venous Disease. — Rochon PJ, Reghunathan A, Kapoor BS, et al. Journal of the American College of Radiology : JACR. 2023.
18. The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. — Kahn SR, Comerota AJ, Cushman M, et al. Circulation. 2014.
19. Rutosides for Treatment of Post-Thrombotic Syndrome. — Morling JR, Broderick C, Yeoh SE, Kolbach DN. The Cochrane Database of Systematic Reviews. 2018.
20. Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial. — Vedantham S, Kahn SR, Marston WA, et al. The New England Journal of Medicine. 2026.
21. ACR Appropriateness Criteria® Radiologic Management of Iliofemoral Venous Thrombosis. — Expert Panel on Interventional Radiology, Farsad K, Kapoor BS, et al. Journal of the American College of Radiology : JACR. 2020.
22. Efficacy and Safety of One-Stop Angiojet Mechanical Thrombectomy Combined With Iliac Vein Stenting in May-Thurner Syndrome Complicated With Acute Iliofemoral Deep Vein Thrombosis. — Shao T, Zhou Y, Wang J, Song Z. Medicine. 2026.
23. Endovascular Management of May-Thurner Syndrome: A Case Report. — Zhang X, Shi X, Gao P, et al. Medicine. 2016.
24. Technical Feasibility and Clinical Efficacy of Iliac Vein Stent Placement in Adolescents and Young Adults With May-Thurner Syndrome. — Bertino FJ, Hawkins CM, Woods GM, et al. Cardiovascular and Interventional Radiology. 2023.
25. May-Thurner Syndrome and Deep Vein Thrombosis: A Series of 8 Patients. — García-García A, Oblitas CM, Galeano-Valle F, et al. Medicina Clinica. 2021.